Abstracts tagged "Outcome measures"

Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Atul Deodhar¹, Laure Gossec², Philip J. Mease³, Xenofon Baraliakos⁴, Lihi Eder⁵, Alan Kivitz⁶, Helena Marzo-Ortega⁷, Frank Behrens⁸, Ana-Maria Orbai⁹, Georg Schett¹⁰, Arthur Kavanaugh¹¹, Dennis McGonagle¹², Christopher Ritchlin¹³, Nuala Brennan¹⁴, Ben Porter-Brown¹⁴, Eva Cullen¹⁴, Matthew R. Thomas¹⁴, Marius Albulescu¹⁴, Alex Godwood¹⁴, Kristian Reich¹⁵ and Laura Coates¹⁶, ¹Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁵University of Toronto, Toronto, ON, Canada, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ⁸Rheumatology, Immunology - Inflammation Medicine, University Hospital Goethe-University & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, ⁹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁰Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ¹¹University of California, San Diego, School of Medicine, San Diego, CA, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹³University of Rochester Medical Center, Canandaigua, NY, ¹⁴MoonLake Immunotherapeutics AG, Zug, Switzerland, ¹⁵MoonLake Immunotherapeutics AG and Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Zug, Switzerland, ¹⁶Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…
Abstract Number: 0442 • ACR Convergence 2025
Beyond the Joints: The Impact of Non-Articular Pain on Patient-Reported Function in a Longitudinal Real-World Early RA Cohort
Charis Meng¹, Marie-France Valois², Caci Julia³, Yvonne Lee⁴, Bindee Kuriya⁵, Gilles Boire⁶, Hugues Allard-Chamard⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Carter Thorne¹¹, Susan J. Bartlett¹², Janet Pope¹³ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²McGill University, Pointe-Claire, QC, Canada, ³Hospital for Special Surgery, New York, ⁴Northwestern University, Chicago, IL, ⁵Mount Sinai Health, Toronto, Canada, ⁶Retired, Sherbrooke, QC, Canada, ⁷Université de Sherbrooke, Sherbrooke, Canada, ⁸University of Manitoba, Winnepeg, Canada, ⁹Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²McGill University, Beaconsfield, QC, Canada, ¹³University of Western Ontario, London, ON, Canada
Background/Purpose: A third of patients with early (e)RA report pain outside the joint or non-articular pain (NAP) despite RA treatment(1). NAP, both regional and widespread,…
Abstract Number: 0227 • ACR Convergence 2025
Malignancy Screening of Dermatomyositis Patients in the Penn State Registry of Inflammatory Myopathies (PRIMO)
Katrina Gonzales¹, William DeKryger², Deepika Pugalenthi Saravanan², Esha Tulsian², Peri Newman³, Jacob Colello², Galen Foulke⁴ and Nancy Olsen⁵, ¹Penn State College of Medicine, Hummelstown, PA, ²Penn State College of Medicine, Hershey, PA, ³Penn State Health/ Penn State College of Medicine, Hershey, PA, ⁴Penn State Health, Hershey, PA, ⁵Penn State University/Milton S Hershey, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is an immune-mediated myopathy characterized by muscle weakness and skin rash that carries an elevated risk of associated malignancy within 5 years…
Abstract Number: 2554 • ACR Convergence 2025
Real-World Observations on Symptom Response and Tolerability of Intravenous Immunoglobulin in Patients with Inflammatory Myopathies through a Nurse-Led Outcomes Monitoring Program in a Home Infusion Setting
Didem Saygin¹, Elizabeth Neal², Edward O'Bryan³, Alisha Smith, PharmD³, Leslie Myers³ and Timothy Walton³, ¹Rush University Medical Center, Chicago, IL, ²CSI Pharmacy, Nash, TX, ³CSI Pharmacy, Nash
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are autoimmune diseases typically characterized by muscle weakness. Intravenous Immunoglobulin (IVIg) is an effective immunomodulatory therapy in patients with refractory…
Abstract Number: 2348 • ACR Convergence 2025
Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
Francesco Fulvio Bizzarri¹, Luis Alberto Menchén Viso², Esther Chamorro De Vega³, Ofelia Baniandrés Rodríguez⁴ and Juan Carlos Nieto², ¹Hospital Universitario Clinico San Cecilio, Granada, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Pharmacy department, Hospital General Universitario Gregorio Marañón.Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain, Madrid, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Immune‐mediated rheumatic diseases (IMRDs) are chronic inflammatory disorders driven by multiple overlapping immunological pathways. Although biologic DMARD monotherapy has substantially improved outcomes, a subset…
Abstract Number: 2142 • ACR Convergence 2025
Multidisciplinary Rheumatology Transition Clinic for Young Adults Shows Improved Experience, Utilization, and Health Maintenance: A Mixed-Methods Evaluation
Hannah Concannon¹, Jasmine Oesch², Sara Mazzarelli², Anne Fields², Keisha-Gaye O'Garo² and Rebecca Sadun³, ¹Duke University School of Medicine, Chapel Hill, NC, ²Duke University School of Medicine, Durham, NC, ³Duke University, Durham, NC
Background/Purpose: The transition from pediatric to adult care can pose a challenge for patients with SLE and other rheumatic diseases. These patients often face preventable…
Abstract Number: 1685 • ACR Convergence 2025
The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease
Raphaele Seror¹, Gabriel Baron², Elodie Perrodeau³, Alena Piatrova⁴, Hendrika Bootsma⁵, Simon Bowman⁶, Jacques-eric GOTTENBERG⁷, Divi Cornec⁸, michele Bombardieri⁹, Suzanne Arends¹⁰, Benjamin A. Fisher¹¹, Wolfgang Hueber¹², Antoine Sreih¹³, Antonia Christodoulou¹⁴, Andre van Maurik¹⁵, Joel van Roon¹⁶, Valerie Devauchelle¹⁷, Peter Gergely¹⁸, Xavier Mariette¹⁹ and Raphael Porcher²⁰, ¹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ²Hôtel-Dieu, Université Paris Cité,, Paris, France, ³Université Paris Descartes Sorbonne Paris Cité, Paris, France, ⁴Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., Paris, Ile-de-France, France, ⁵UMCG, Groningen, Netherlands, ⁶University Hospitals Birmingham, Birmingham, United Kingdom, ⁷Hautepierre Hospital, STRASBOURG, Alsace, France, ⁸Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR¹²²⁷: LBAI, Brest, France, Brest, France, ⁹Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands, ¹¹King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, ¹²Novartis Pharmaceuticals, Basel, Switzerland, ¹³Cullinan Therapeutics, New York, NY, ¹⁴BMS, Princeton, NJ, ¹⁵GlaxoSmithKline, Stevenage, United Kingdom, ¹⁶Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht PO BOX ⁸⁵⁵⁰⁰, ³⁵⁰⁸ GA, Netherlands, Utrecht, Netherlands, ¹⁷UBO, Brest, France, ¹⁸Novartis Biomedical Research, Basel, Switzerland, ¹⁹Université Paris-Saclay, Le Kremlin Bicetre, France, ²⁰Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France
Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…
Abstract Number: 1411 • ACR Convergence 2025
Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
Conor Coyle¹, Sarah Yazji², Sruthi Murthy³, Philip Helliwell⁴, Andra Balanescu⁵, Juan Cañete⁶, Emmanuelle Dernis⁷, Uta Kiltz⁸, Ying Ying Leung⁹, Ana-Maria Orbai¹⁰, PENELOPE PALOMINOS¹¹, Josef Smolen¹², Maarten de Wit¹³, Laure Gossec¹⁴ and Laura Coates¹⁵, ¹Oxford University Hospitals, Reading, United Kingdom, ²South Texas Health System GME Consortium, Texas A&M College of Medicine, Texas, USA, College Station, TX, ³Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ⁵UNIVERSITY OF MEDICINE AND PHARMACY CAROL DAVILA, Bucharest, Romania, ⁶Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁷Rheumatology Department, Le Mans Central Hospital, Le Mans, France, LE MANS, France, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumatology Department, Singapore General Hospital, Singapore, Singapore, Singapore, Singapore, ¹⁰Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹¹Hospital Lifeplus Litoral Norte, Xangri-lá, Brazil, Porto Alegre, Rio Grande do Sul, Brazil, ¹²Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ¹³Patient Research Partner, Stichting Tools, Amsterdam, Netherlands, ¹⁴Sorbonne Universite and Pitie-Salpetriere Hospital, Paris, France, ¹⁵Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: Treat to target management is recommended in psoriatic arthritis (PsA) to improve disease control and patient quality of life. Minimal disease activity (MDA) criteria…
Abstract Number: 1076 • ACR Convergence 2025
Racial Differences in Real-World Use of Urate-Lowering and Adjunctive Therapies for Gout: A 10-Year Propensity-Matched Cohort Study
Michael Hamilton¹, Justin Riley Lam², Emmanuel Otabor³, Laith Alomari³, Maxim Barnett³, Arthur Lau⁴ and Irene Tan⁵, ¹Jefferson Einstein Hospital, Philadelphia, Philadelphia, PA, ²Jefferson Einstein Hospital, Philadelphia, PA, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA, ⁵Einstein Healthcare Network Philadelphia - Jefferson Health, Bala Cynwyd, PA
Background/Purpose: Although achieving target serum urate (SU) and reducing cardiovascular events are cornerstones of gout management, little is known about contemporary treatment patterns across racial…
Abstract Number: 0569 • ACR Convergence 2025
ASAS recommendations on reporting outcomes of core outcome set instruments in axial spondyloarthritis clinical trials
Floris A. van Gaalen¹, Victoria Navarro-Compan², Xenofon Baraliakos³, Filip Van den Bosch⁴, Lianne S. Gensler⁵, Ihsane Hmamouchi⁶, Robert Landewé⁷, Pedro Machado⁸, Helena Marzo-Ortega⁹, Valeria Rios Rodriguez¹⁰, Denis Poddubnyy¹¹, Sofia Ramiro¹² and Désirée Van Der Heijde¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁶Health Sciences Research Center (CReSS).Faculty of Medicine, International University of Rabat, Rabat, Morocco, ⁷Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁸Department of Rheumatology, University College London, and Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS Trust, Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ⁹NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds, Leeds, United Kingdom, ¹⁰Charité-Universitétsmedizin Berlin, corporate member of Freie universität Berlin and Humboldt-Universität zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ¹¹Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ¹²Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The recently updated Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS)includes an agreed minimum set of instruments that should be used in…
Abstract Number: 0441 • ACR Convergence 2025
Charting the Course of Worsening: Utilizing Standard Outcomes to Define Worsening for Pathophysiological Insights into RA
Charis Meng¹, Caci Julia², Kelsey Gripp², Deanna Jannat-Khah¹, Yvonne Lee³, Susan J. Bartlett⁴, Clifton Bingham⁵ and Vivian Bykerk¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Northwestern University, Chicago, IL, ⁴McGill University, Beaconsfield, QC, Canada, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: RA disease worsening contributes to joint damage and cardiovascular disease. While measures of improvement are established in RA, we do not have uniform definitions…
Abstract Number: 0225 • ACR Convergence 2025
Positive anxiety, depression and/or fibromyalgia screening on validated MDHAQ indices is seen in 30-50% of routine care patients with all rheumatic diagnoses
Juan Schmukler¹, Tengfei Li² and Theodore Pincus¹, ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Comorbid anxiety (ANX), depression (DEP), and fibromyalgia(FM) are reported as more common in patients with rheumatoid arthritis (RA) and other rheumatic diagnoses than in…
Abstract Number: 2545 • ACR Convergence 2025
Prevalence, Clinical Correlations and Outcomes of Cryoglobulinemic Vasculitis: a Retrospective Monocentric Study (2013–2023)
Valeria Manfrè¹, elena treppo², Maria Pillon³, Maria De Martino⁴, Cinzia Fabro⁵, Miriam Isola⁴, Martina Fabris⁶, Francesco Curcio⁶ and Luca Quartuccio¹, ¹Division of Rheumatology, Department of Medicine (DMED), Academic Hospital "Santa Maria della Misericordia", ASUFC, University of Udine, Udine, Italy, Udine, Italy, ²Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, ³Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy, Udine, Italy, ⁴Institute of Statistics, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁵Division of Rheumatology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy, ⁶Institute of Clinical Pathology, Department of Medicine, University of Udine, Udine, Italy., Udine, Italy
Background/Purpose: Cryoglobulinemic vasculitis (CryoVas) is a rare immune-complex-mediated disorder, often associated with hepatitis C virus (HCV) infection, autoimmune diseases (ADs), or other etiologies. Despite its…
Abstract Number: 2334 • ACR Convergence 2025
Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
Dafne capelusnik¹, Philip Gardiner², Elena Nikiphorou³, Désirée Van Der Heijde⁴, Robert Landewé⁵, Astrid Van Tubergen⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ²Altnagelvin Hospital, Londonderry, United Kingdom, ³King’s College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, ⁶Maastricht university, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+ & Maastricht University, Maastricht, Limburg, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: The MOBILITY study, a study on spinal mobility measures in healthy individuals, showed that the Bath Ankylosing Spondylitis Metrology Index (BASMI) often overestimates spinal…
Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Philip Conaghan¹, nathaniel katz², Asger Bihlet³, Laus W Wullum⁴, Kerry af Forselles⁵, C Michael Perkins⁵, Bernadette Hughes⁶, Claire Herholdt⁷ and Iwona Bombelka⁸, ¹University of Leeds, Leeds, United Kingdom, ²Rin Sof Innovation, Ltd, Boston, MA, ³NBCD A/S, Herlev, Denmark, ⁴Omicron A/S, Copenhagen, Denmark, ⁵Levicept, Sandwich, United Kingdom, ⁶Levicept, Ashtead, United Kingdom, ⁷Levicept Ltd, Ashtead, United Kingdom, ⁸Levicept, Sandwich, Kent, United Kingdom
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…

« Previous Page
1
…
4
5
6
7
8
…
59
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].